Asia Pacific Nuclear Medicine Market Size & Outlook

Name: Asia Pacific Nuclear Medicine Market Size & Outlook
Creator: Grand View Research
License: https://www.grandviewresearch.com/horizon/info/terms-of-use

The nuclear medicine market in Asia Pacific is expected to reach a projected revenue of US$ 8,594.5 million by 2033. A compound annual growth rate of 7.3% is expected of Asia Pacific nuclear medicine market from 2026 to 2033.

Asia Pacific nuclear medicine product outlook (Revenue, USD million, 2021-2033)
- Diagnostics
  - SPECT
    - TC-99m
    - TL-201
    - GA-67
    - I-123
    - Others
  - PET
    - F-18
    - SR-82/RB-82
    - PYLARIFY (piflufolastat F 18)
    - Illuccix (gallium Ga 68 gozetotide)
    - Others
- Therapeutics
  - Alpha Emitters
    - RA-223
    - Others
  - Beta Emitters
    - I-131
    - Y-90
    - SM-153
    - Re-186
    - Lu-177
    - Others
  - Brachytherapy
    - Cesium-131
    - Iodine-125
    - Palladium-103
    - Iridium-192
    - Others
Asia Pacific nuclear medicine application outlook (Revenue, USD million, 2021-2033)
- Cardiology
  - SPECT
  - PET
  - Therapeutic Applications
- Neurology
- Oncology
- Thyroid
  - SPECT
  - Therapeutic Applications
- Lymphoma
- Bone Metastasis
  - SPECT
  - Therapeutic Applications
- Endocrine Tumor
- Pulmonary Scans
- Urology
- Other
Asia Pacific nuclear medicine end use outlook (Revenue, USD million, 2021-2033)
- Hospitals
- Diagnostic Centers
- Others

Asia Pacific Nuclear Medicine Market Size & Outlook

Sign up - it's easy, and free!